Rep. DeLauro Tries To Block FDA Outsourcing Of Antibiotic Label Updating
Executive Summary
FDA's efforts to rely on outside support to carry out its mission have again met with resistance from House Appropriations Subcommittee Chair Rosa DeLauro, D-Conn., who is arguably the agency's most powerful public benefactor
You may also be interested in...
Antibiotic Promotions Can't Rely On In Vitro Claims, Even If Labeling Might
Drug makers cannot promote their products to health care professionals by citing in vitro studies as if they are clinical evidence, FDA said in a warning letter
Antibiotic Promotions Can't Rely On In Vitro Claims, Even If Labeling Might
Drug makers cannot promote their products to health care professionals by citing in vitro studies as if they are clinical evidence, FDA said in a warning letter
FDA Should Outsource Elements Of Antibacterial Labeling Updates - Cmte.
FDA should apply the Clinical and Laboratory Standards Institute's recommendations for updating susceptibility test information in systemic antibacterial drug product labeling, the Anti-Infective Drugs Advisory Committee unanimously recommended